AstraZeneca's Three-in-One COPD Inhaler Succeeds in Phase III Trial Post author:Sam Post published:January 25, 2018 Post category:BioPharma Astra has Glaxo and its COPD treatment Trelegy Ellipta squarely in its sights. Source: BioSpace You Might Also Like How This Drug Candidate Could be a Winner in Gilead's Pipeline March 20, 2017 Bay Area's CytomX Surges as Bristol-Myers Squibb Signs Up for 8 More Projects With $200 Million Upfront in Deal Totaling $5 Billion March 19, 2017 6 Blood Testing Startups Hoping to be The Next Theranos – The Good Version January 11, 2018
Bay Area's CytomX Surges as Bristol-Myers Squibb Signs Up for 8 More Projects With $200 Million Upfront in Deal Totaling $5 Billion March 19, 2017
